Get notified when SMNR files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (worsened) — Substantial doubt persists given cash of only $0.1M and operating cash outflow of $2.3M against minimal liquidity; the reported $154.3M net loss is overwhelmingly non-cash (Business Combination charges), not cash burn.
  • Material Weakness (unchanged) — Material weaknesses in internal controls over carve-out financial statements and stock-based compensation remain unremediated.
  • Controlled Company (unchanged) — Company remains a controlled entity; no change in control structure disclosed.
  • Cryptocurrency Treasury Strategy (unchanged) — Filing maintains a standing Risks Related to Cryptocurrency disclosure for a named Bitcoin treasury/financing strategy that has not been implemented or tested (1940-Act risk). On minimal cash with going-concern doubt, this non-standard treasury pivot is material even when a related financing line moves out of Recent Developments.
OTC: SMNR Semnur Pharmaceuticals, Inc. S-1/A

SMNR starts 2nd Phase 3 trial as cash falls to $0.1M; $152.6M deficit jump mostly non-cash

Filed December 19, 2025 · Compared to S-1 Oct 21, 2025 · ~1 min read

Key Changes

  • high

    Net loss of $154.3M for nine months ended Sep 2025 is overwhelmingly non-cash (operating cash outflow only $2.3M); accumulated deficit jumped $152.6M in three months to $269.6M, driven by Business Combination charges.

    MD&A: Operating Losses verify on EDGAR →
  • high

    Cash and cash equivalents stood at $0.1M as of Sep 30, 2025; company has disclosed substantial doubt about ability to continue as a going concern and will require near-term financing.

    MD&A: Cash Position / Risk Factors: Going Concern verify on EDGAR →
  • high

    Second Phase 3 study for SP-102 initiated in Sep 2025, advancing the confirmatory trial typically required for FDA approval beyond the pivotal Phase 3 completed in Mar 2022.

    MD&A: Clinical Development verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.

Partner

Trade SMNR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 27, 2026 · How we verify